To require the Secretary of Energy to establish a centralized resource for access to data to facilitate biological research through enabling advanced computational methods such as artificial intelligence, and for other purposes.
Introduced June 11, 2026 · Last action June 11, 2026
Plain English Summary
This bill requires the Department of Energy to set up a centralized database and resource center that makes biological research data openly accessible to scientists and researchers, with tools to use artificial intelligence and advanced computational methods to analyze that data. The goal is to accelerate biological research by removing barriers to accessing datasets that are currently scattered across different institutions and agencies.
Who benefits
Academic researchers and university biology departments; pharmaceutical and biotechnology companies developing new drugs and therapies; artificial intelligence and machine learning software companies; federal research institutions (NIH, NSF-funded labs); startup biotech firms seeking access to large datasets; hospitals and medical research centers conducting clinical studies; foreign and domestic research teams using U.S. biological datasets.
Who pays / loses
U.S. taxpayers fund the Department of Energy's development and maintenance of this centralized database system; companies and institutions currently profiting from proprietary control over biological datasets may lose competitive advantage if data becomes more widely available; federal agencies currently managing siloed biological datasets may incur integration and coordination costs.
Funding & Lobbying Interests
Biotechnology and pharmaceutical industry groups (e.g., Biotechnology Industry Organization, Pharmaceutical Research and Manufacturers of America) typically lobby for expanded data access and AI-enabled research infrastructure. Academic research institutions and university associations support centralized data platforms. AI and software companies (including cloud computing providers) benefit from expanded datasets and computational research workloads. The Department of Energy's national laboratories and ARPA-E have existing interests in biological data infrastructure. Sponsors of such legislation typically receive contributions from technology sector donors, research institution leadership, and life sciences industry PACs.
Political Impact
Affected Groups
Biological and medical researchers (estimated 200,000+ active life science researchers in U.S. universities and private labs); pharmaceutical and biotech companies (approximately 5,000+ firms in U.S. biotech sector); artificial intelligence researchers and machine learning engineers using biological datasets; undergraduate and graduate students in biology, medicine, and computational biology; international research collaborators with U.S. institutional affiliations; patients who may benefit from faster drug discovery and medical breakthroughs enabled by AI-accelerated research.
Political Subtext
Proponents frame this as necessary infrastructure for American competitiveness in AI-driven biology research, arguing centralized access accelerates medical breakthroughs and keeps cutting-edge research in the U.S. rather than moving to countries with more open data policies. They emphasize benefits for public health and economic growth. Critics might argue the bill lacks oversight mechanisms for data privacy and security, could create cybersecurity vulnerabilities by centralizing sensitive biological data, or may insufficiently protect intellectual property interests of companies that contributed data. The non-partisan case for centralized research infrastructure is well-established (NIH and NSF have made similar arguments for open science), though implementation details on data governance, security protocols, and cost-sharing are critical and not specified in this bill text.
Real-World Stakes
If enacted, the U.S. would join other advanced economies (EU, China, Canada) in creating national biological data commons accessible to AI researchers. Success depends on whether the resource achieves high-quality, well-organized, secure data that attracts researchers—similar to how NIH's Gene Expression Omnibus and the Cancer Genome Atlas have accelerated research by democratizing access. Failure risks wasting resources on an unused or poorly-designed platform. The bill does not specify budgets, governance structure, data security standards, or whether participation is mandatory or voluntary, leaving implementation and real-world impact unclear. Analogous efforts like the NIH All of Us Research Program (launched 2018, $1.46 billion authorized) show both potential (millions of health records accessible) and challenges (recruitment targets missed, privacy concerns).
Sponsor
Sponsor information not available.
Vote Record
No recorded votes.
Campaign Finance — Primary Sponsor
No campaign finance data available yet.
501(c)(4) disclosure: Contributions from 501(c)(4) "dark money" organizations are not required to be publicly disclosed and are not reflected in the figures above. Data sourced from FEC public disclosure filings.
Community Discussion
Share this bill
Sign in to join the discussion.
No comments yet. Be the first.